Lutetium-177 catalase injection for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new radioactive drug (Lutetium-177 attached to an enzyme called catalase) that is injected directly into tumors. It is for people with advanced solid tumors, like liver, ovarian, or prostate cancer, who have run out of standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old and able to do your daily activities (ECOG score 0 or 1).
- You have an advanced solid tumor (like liver, ovarian, or prostate cancer) that standard treatments have stopped working for or you cannot tolerate.
- Your doctor expects you to live at least 3 more months, and you have at least one tumor that is 1 cm or larger and can be injected directly.
- Your blood counts, liver, and kidney function must be within safe limits (checked by lab tests).
- You agree to use effective birth control during and for 6 months after the study (if applicable), and you are not pregnant or breastfeeding.
- You can lie flat for 30 minutes, do not have severe claustrophobia, and are willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive drug called 177Lu-LNC1004 for people with a type of thyroid cancer that is no longer responding to standard treatments. The drug targets a protein called FAP found on tumor cells, which may help shrink tumors and slow disease progression.
This trial tests a new radioactive drug, Lutetium-177 FAP-75, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and deliver radiation directly to cancer cells, potentially slowing tumor growth.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.